Get the Stockscreener App
5.01
2.91%
-0.15
Xeris Biopharma Holdings Inc stock is traded at $5.01, with a volume of 2.54M.
It is down -2.91% in the last 24 hours and up +15.70% over the past month.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
See More
Previous Close:
$5.16
Open:
$5.19
24h Volume:
2.54M
Relative Volume:
0.85
Market Cap:
$736.57M
Revenue:
$181.41M
Net Income/Loss:
$-59.56M
P/E Ratio:
-11.93
EPS:
-0.42
Net Cash Flow:
$-38.83M
1W Performance:
+6.37%
1M Performance:
+15.70%
6M Performance:
+44.38%
1Y Performance:
+166.49%
1-Day Range:
$5.00
$5.23
1-Week Range:
$4.255
$5.275
52-Week Range:
$1.73
$6.07
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Name
Xeris Biopharma Holdings Inc
Sector
Industry
Phone
844-445-5704
Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
5.01 | 736.57M | 181.41M | -59.56M | -38.83M | -0.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Aug-28-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Craig Hallum | Buy |
| Nov-17-21 | Initiated | SVB Leerink | Outperform |
| Oct-29-21 | Initiated | H.C. Wainwright | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-18-20 | Initiated | Piper Sandler | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Leerink Partners | Outperform |
| Jul-16-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Xeris Biopharma Holdings Inc Stock (XERS) Latest News
Xeris Biopharma Holdings First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Earnings Call Transcript - Insider Monkey
Oppenheimer Increases Price Target for Xeris Biopharma (XERS) to $7 | XERS Stock News - GuruFocus
XERS: Oppenheimer Raises Price Target for Xeris Biopharma Holdings | XERS Stock News - GuruFocus
Xeris Biopharma: Q1 Earnings Snapshot - New Haven Register
Xeris Biopharma Reports Record First Quarter 2025 Financial Results - BioSpace
Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Xeris Biopharma Holdings Inc (XERS) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Advancements - GuruFocus
Xeris Biopharma Reports Strong Q1 2025 Growth - TipRanks
Xeris Pharmaceuticals Reports Strong Earnings and Growth - TipRanks
Xeris Biopharma raises revenue guidance for 2025 to $260M-$275M amid strong Recorlev growth - MSN
Xeris Biopharma Holdings, Inc. SEC 10-Q Report - TradingView
Transcript : Xeris Biopharma Holdings, Inc., Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
Market Recap: Xeris Biopharma Holdings Inc (XERS)’s Positive Momentum, Closing at 4.48 - DWinneX
Xeris Biopharma Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Xeris Biopharma (XERS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
XERS Revenue Surpasses Expectations with Strong Q1 Performance | XERS Stock News - GuruFocus
MetLife Investment Management LLC Has $296,000 Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - The AM Reporter
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Bought by Wells Fargo & Company MN - Defense World
Xeris Pharmaceuticals Q1 2025 Earnings Preview - MSN
Xeris Biopharma Holdings: Looking For More Growth In Q1 Earnings (NASDAQ:XERS) - Seeking Alpha
Barclays PLC Purchases 23,170 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings Inc [XERS] Records 50-Day SMA of $4.51 - knoxdaily.com
Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025 - BioSpace
LPL Financial LLC Decreases Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma (XERS) Projected to Post Earnings on Thursday - Defense World
Prepare Yourself for Liftoff: Xeris Biopharma Holdings Inc (XERS) - Sete News
Market Momentum Report: Xeris Biopharma Holdings Inc (XERS)’s Positive Close at 4.41 - DWinneX
Xeris Biopharma Holdings Inc (XERS) stock analysis: A simple moving average approach - uspostnews.com
Analysts Expect Breakeven For Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Before Long - simplywall.st
Recent Insider Activity Suggests Potential Gains for Xeris Biopharma Holdings Inc (XERS) - knoxdaily.com
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Bought by Russell Investments Group Ltd. - Defense World
Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To Profit - Yahoo
Xeris Biopharma Holdings Inc’s Banking’s 100-Day Moving Average at 3.96: Will the Stock Break Through? - investchronicle.com
Xeris Biopharma Holdings Inc (XERS) Performance and Fundamentals Dashboard tells a completely different story - Sete News
Understanding the Risks of Investing in Xeris Biopharma Holdings Inc (XERS) - knoxdaily.com
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by Geode Capital Management LLC - Defense World
Is Xeris Biopharma Holdings Inc. (XERS) the Best Multibagger Penny Stock to Buy According to Billionaires? - Insider Monkey
10 Best Multibagger Penny Stocks to Buy According to Billionaires - Insider Monkey
Are Xeris Biopharma Holdings Inc (XERS) shares a good deal now? - uspostnews.com
Market Watch: Xeris Biopharma Holdings Inc (XERS)’s Noteworthy Drop, Closing at 4.02 - DWinneX
JPMorgan Chase & Co. Has $3.54 Million Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Alliancebernstein L.P. Reduces Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Sees Large Growth in Short Interest - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Acquired by Vanguard Group Inc. - Defense World
Raymond James Financial Inc. Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Wellington Management Group LLP Sells 6,532 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Purchased by Prudential Financial Inc. - Defense World
Xeris Biopharma Holdings Inc [XERS] stock was sold by Hecht Beth at the price of US$0.22 million - knoxdaily.com
Xeris Biopharma Holdings Inc Stock (XERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xeris Biopharma Holdings Inc Stock (XERS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hecht Beth | See Remarks |
Mar 20 '25 |
Sale |
5.43 |
40,000 |
217,244 |
1,353,510 |
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):